Skip to main content
SpringerLink
Log in

Accelerated Path to Cures

  • Book
  • © 2018

Overview

Editors:
  1. Josep Bassaganya-Riera

    1. Nutritional Immunology and Molecular Medicine Laboratory, Biocomplexity Institute of Virginia Tech, Blacksburg, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Details the role of modeling and computational approaches in precision medicine

  • Highlights the progress towards precision medicine

  • Advances Path to Cures

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (5 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Introduction to Accelerated Path to Cures and Precision Medicine in Inflammatory Bowel Disease

    • Josep Bassaganya-Riera, Raquel Hontecillas
    Pages 1-6

  3. Computer-Aided Drug Discovery

    • Pinyi Lu, David R. Bevan, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, Josep Bassaganya-Riera
    Pages 7-24

  4. Preclinical Studies: Efficacy and Safety

    • Nuria Tubau-Juni, Raquel Hontecillas, Marion Ehrich, Andrew Leber, Victoria Zoccoli-Rodriguez, Josep Bassaganya-Riera
    Pages 25-40

  5. From Nutritional Immunology to Drug Development

    • Meghna Verma, Raquel Hontecillas, Vida Abedi, Andrew Leber, Pinyi Lu, Nuria Tubau-Juni et al.
    Pages 41-56

  6. Development of Synthetic Patient Populations and In Silico Clinical Trials

    • Ramin Zand, Vida Abedi, Raquel Hontecillas, Pinyi Lu, Nariman Noorbakhsh-Sabet, Meghna Verma et al.
    Pages 57-77

  7. Back Matter

    Pages 79-82
    Download chapter PDF
Back to top

Keywords

About this book

Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures. 

Editors and Affiliations

  • Nutritional Immunology and Molecular Medicine Laboratory, Biocomplexity Institute of Virginia Tech, Blacksburg, USA

    Josep Bassaganya-Riera

About the editor

Dr. Josep Bassaganya-Riera is a serial entrepreneur and innovator who has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) at the Biocomplexity Institute of Virginia Tech since 2002. The NIMML tackles unsolved challenges in complex human diseases with unmet clinical needs. His research has received over $55 million in competitive R&D funding to combine advanced computational technologies with preclinical and clinical experimentation. The NIMML translates novel scientific discoveries into commercial applications that address unmet patient or consumer needs. Dr. Bassaganya-Riera has published over 150 peer-reviewed publications in reputable biomedical journals, founded 3 successful biotech companies (Pervida, Biotherapeutics and Landos Biopharma), and was recently named 2017 Innovator of the Year by the Roanoke-Blacksburg Technology Council. Dr. Bassaganya-Riera, and his companies have been active members of a statewide group that supports the planning behind the Governor’s 2015 Virginia Bioscience Initiative.  This initiative calls for Virginia to be in the top three pharmaceutical regions by 2023. Dr. Bassaganya-Riera was a featured presenter at the Governor’s Forum on Bio and Big Data.


Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation